<DOC>
	<DOCNO>NCT00506051</DOCNO>
	<brief_summary>The main purpose trial look see add ZD6474 ( 100 mg 300mg tablet ) Alimta chemotherapy patient non-small cell lung cancer safe help control symptoms disease good chemotherapy alone .</brief_summary>
	<brief_title>ZD6474 ( Vandetanib ) + Alimta Combo Study</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Confirmed advance metastatic nonsmall cell lung cancer Failure firstline chemotherapy 1 measurable lesion RECIST Previous chemotherapy radiotherapy within 4 week Significant cardiac event , arrythmias cardiac condition Unacceptable laboratory measurement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>lung cancer</keyword>
	<keyword>alimta</keyword>
	<keyword>vandetanib</keyword>
	<keyword>phase 1</keyword>
</DOC>